研究单位：[1]Zenas BioPharma (USA), LLC[2]Peking Union Medical College Hospital,Beijing,Beijing,China,100730[3]Beijing Tongren Hospital, CMU,Beijing,China[4]Peking University Third Hospital,Beijing,China[5]Third Xiangya Hospital of Central South University,Changsha,China[6]Xiangya Hospital Central South University,Changsha,China[7]Chongqing Aier General Hospital,Chongqing,China[8]The Second Hosptial of Dalian Medical University,Dalian,China[9]The Second Hosptial of Anhui Medical University,Hefei,China[10]Affiliated Eye Hospital of Nanchang University,Nanchang,China
研究目的：
The investigational drug, ZB001 is a humanized IgG1κ monoclonal antibody targeting human IGF-1R. The study is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics（PK）/pharmacodynamics (PD) profile of ZB001 in Chinese patients with Thyroid Eye Disease.
